18F-florbetaben

Phase 2Radiopharmaceutical

NNational Institute of Mental Health (NIMH)

18F-florbetaben is one of 72 therapeutic programs targeting Alzheimer disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alzheimer DiseaseRecruiting

Alzheimer's DiseaseRecruiting

Parkinson's DiseaseRecruiting

Alzheimer DiseasePhase 2

Recruiting

Alzheimer's DiseasePhase 1

Recruiting

Parkinson's DiseasePhase 1

Recruiting

Competition

Competitive Landscape

171 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Phase 3

2 2

Tirazone

Karxt

3 4

Karx-EC

Bristol-Myers Squibb

Phase 3

2 5

Aquasol E

NNational Eye Institute (NEI)

Aricept

2 7

Naproxen Sodium

Namenda

1 9

Exelon

Novartis

Phase 2

1 10

Depo-Provera

Eli Lilly

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Alzheimer Disease

NCT04576793

Q2 2030

Phase 1Recruiting

Alzheimer's Disease

NCT07169630

Q4 2030

Phase 1Recruiting

Parkinson's Disease

NCT04396873

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)

Recruiting·NNational Institute of Mental Health (NIMH)·Phase 1·NCT07169630·90 enrolled

Alzheimer disease1 trial

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Recruiting·PPatrick Lao·Phase 2·NCT04576793·100 enrolled

Parkinson's Disease1 trial

Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Recruiting·NNational Institute of Mental Health (NIMH)·Phase 1·NCT04396873·184 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for 18F-florbetaben. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 18F-florbetaben. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Mental Health (NIMH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical
Highest Phase: Phase 2[1]
Company: NNational Institute of Mental Health (NIMH)

18F-florbetaben

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2030

Q4 2030

Trials by Indication[1]

Alzheimer's Disease1 trial

Alzheimer disease1 trial

Parkinson's Disease1 trial

References

Drug Info

Quick Facts

Related News